Heimann N.

Heimann N.

Auto-generated profile, based on publicly available information

Heimann N.

District Hospital named after Prof. Roman Drews, Chodzież

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Clinical Medicine And Health Research Journal
Verified
Journal Article
Open access
PDF file
HNHeimann N
Heimann N
HIHandzlik I
Handzlik I
BMBarbara Myszkowska
Barbara Myszkowska
Obesity significantly impairs female reproductive outcomes through mechanisms including anovulation, reduced implantation, and increased miscarriage risk. Glucagon-like peptide-1 receptor agonist (GLP-1 RAs), particularly semaglutide (Ozempic), demonstrate robust weight reduction efficacy and potential reproductive benefits in women with obesity and polycystic ovary syndrome (PCOS). Emerging evidence suggests improvements in menstrual cyclicity, oocyte quality, and spontaneous conception rates, mediated by both metabolic and weight loss-independent mechanisms such as reduced inflammation and androgen levels. Clinical data from randomized controlled trials and observational cohorts provide preliminary reassurance that inadvertent first-trimester exposure to semaglutide does not increase major congenital malformation risk, though concerns from animal studies necessitate cautious use. Regulatory authorities recommend discontinuation of semaglutide at least two months prior to conception, emphasizing preconception counseling and reliable contraception. Compared to other anti-obesity pharmacotherapies, GLP-1 RAs show a more favorable reproductive safety profile. However, substantial knowledge gaps remain regarding long-term reproductive outcomes, live birth rates, and offspring development, warranting further prospective studies and pregnancy registry data. This review synthesizes current medical evidence on the “Ozempic pregnancy phenomenon,” offering clinical guidance for reproductive-aged women prescribed semaglutide and highlighting priorities for future research in reproductive endocrinology.

1 September 2025 in Clinical Medicine And Health Research Journal
Verified
Journal Article
Open access
PDF file
BMBarbara Myszkowska
Barbara Myszkowska
ZPZawada- Wiśniewska P.
Zawada- Wiśniewska P.
HNHeimann N.
Heimann N.
HIHandzlik I.
Handzlik I.
MKMateusz Krakowiak
Mateusz Krakowiak
Patients and clinicians face tough choices when standard schizophrenia treatments don’t bring relief. Pharmaceutical treatments have advanced over decades, but 30% of people with schizophrenia still experience symptoms that don’t respond well to conventional approaches. Treatment resistance remains the biggest problem in psychiatric care today. Surgical interventions have emerged as alternatives to think over for patients who’ve tried all first-line treatments. Antipsychotic medications are still the foundations of schizophrenia treatment protocols. The latest research suggests that targeted surgical procedures might offer hope for specific patient groups. These interventions—including Deep Brain Stimulation (DBS), Transcranial Magnetic Stimulation (TMS), and experimental approaches—mark a major shift from traditional management strategies. Schizophrenia treatment’s history shows a steady development from institutional confinement to community-based care. Psychosocial supports now work alongside pharmacological approaches. We have a long way to go, but we can build on this progress. Patients with treatment-resistant forms of the disorder often experience lower quality of life and major functional impairment, even when they follow first-line treatment recommendations. This piece gets into the evidence that compares surgical and traditional approaches for managing schizophrenia symptoms and treatment outcomes. We want to provide a complete overview of current treatment options and how well they work by analyzing clinical trial data, neuroimaging findings, and patient-reported experiences. It also explores the factors that should guide shared decision-making between patients and their healthcare providers as they evaluate these interventions.

1 September 2025 in Clinical Medicine And Health Research Journal
Verified
Journal Article
Open access
PDF file
HNHeimann N
Heimann N
HIHandzlik I
Handzlik I
BMBarbara Myszkowska
Barbara Myszkowska
This review explores the cognitive effects of psychotropic medications with a particular emphasis on memory function across different age groups. Drawing on evidence from 94 meta-analyses and multiple clinical and preclinical studies, the article examines how antidepressants, antipsychotics, and other psychiatric drugs influence learning, attention, and memory performance. While selective serotonin reuptake inhibitors (SSRIs) may transiently impair memory during treatment initiation, long-term effects are often neutral or mildly positive. Tricyclic antidepressants (TCAs), however, carry substantial anticholinergic burden, leading to attention deficits and memory impairment, especially in elderly patients. Antipsychotic use in older adults is associated with accelerated cognitive decline and increased dementia risk, highlighting the importance of cautious prescribing. In contrast, aripiprazole stands out for its unique pharmacological profile, demonstrating favorable outcomes on working memory, verbal fluency, and executive function, while avoiding common metabolic and prolactin-related side effects. Clinical recommendations emphasize the need for individualized treatment selection, minimizing anticholinergic load, and regular monitoring of cognitive function. Ultimately, the preservation of memory and cognitive integrity should be considered an essential therapeutic goal alongside symptom management in psychiatric care.

1 September 2025 in Clinical Medicine And Health Research Journal
Verified
Journal Article
Open access
ŁAŁączkowski A.
Łączkowski A.
HNHeimann N.
Heimann N.
BMBarbara Myszkowska
Barbara Myszkowska
ZPZawada-Wiśniewska P.
Zawada-Wiśniewska P.
HIHandzlik I.
Handzlik I.
Friendship betrayal delusions represent a growing psychiatric phenomenon within the spectrum of 21st century civilization diseases. Characterized by fixed false beliefs about the malicious intentions of trusted individuals, these delusions are influenced by neurobiological vulnerabilities, particularly dopaminergic dysregulation in mesolimbic pathways, and psychosocial factors such as social isolation, early attachment disruptions, and digital hyperconnectivity. They frequently co-occur with depression, anxiety, metabolic syndrome, and sleep disturbances, complicating diagnosis and treatment. Differentiation from borderline personality disorder, PTSD, and other psychiatric conditions requires structured clinical interviews and detailed assessment. Current treatment approaches integrate second-generation antipsychotics, such as risperidone and aripiprazole, with specialized cognitive-behavioral therapy for psychosis. Despite challenges in long-term management, these interventions show promising outcomes, emphasizing the importance of a comprehensive biopsychosocial understanding of friendship betrayal delusions as modern lifestyle-related psychiatric disorders.